US Credit Risk Transfer & Synthetic Risk Transfer
North American "SRT" is a functional category, not a single harmonised regime. The US market is bifurcated: a large, visible GSE credit risk transfer complex and an emerging but opaque bank synthetic securitisation channel seeking capital relief under existing rules.
Executive Summary
The US does not have a Europe-style named "SRT" supervisory approval regime equivalent to CRR Articles 244–245 plus ECB/PRA notification frameworks. Instead, the prudential rules recognise synthetic securitisation for capital purposes if specified operational criteria are met, and for directly issued CLNs the Federal Reserve has handled eligibility through interpretive approval letters. Confirmed
The best-documented North American market is the GSE CRT complex. From 2013 through year-end 2023, Fannie Mae and Freddie Mac transferred credit risk on $6.7 trillion of single-family reference-pool UPB with $210.2 billion of cumulative risk in force; in 2023 alone they transferred risk on $421.8 billion of UPB. Confirmed
The private US bank-originated SRT market is real but opaque. The Federal Reserve's 2024 legal-interpretation page shows approvals for Ally, Truist, Merchants Bancorp, JPMorgan, Citigroup, and HSBC North America to treat CLN issuances as synthetic securitisations for capital purposes. Confirmed No comprehensive official public dataset for US bank SRT issuance volume, outstanding, or investor concentration was verified. That opacity is itself a central finding. Estimated
The US Basel III Endgame remains unfinished in published rule form as of March 2026. Tighter capital rules would generally strengthen the economic case for US bank SRT usage. The July 2023 NPR would also prohibit recognition of synthetic excess spread in synthetic securitisations—a meaningful structural constraint. Confirmed
Product Taxonomy
North American risk-transfer structures
Comprehensive map| Product | Structure | Capital Relief? | Transparency | Provenance |
|---|---|---|---|---|
| GSE CRT (CAS / STACR) | Trust-issued notes referencing mortgage pools; investors take mezzanine loss layers | GSE capital framework (FHFA) | High (public deals) | Confirmed |
| GSE Insurance / Reinsurance (CIRT / ACIS) | Insurance-based coverage with collateralisation; Freddie's ACIS, Fannie's CIRT | GSE capital framework | Moderate (10-K disclosure) | Confirmed |
| Bank SPV-issued CLNs | SPV issues CLNs; proceeds collateralise CDS/guarantee on bank's retained portfolio | Yes (synthetic securitisation rules) | Low (private placement) | Confirmed |
| Bank directly issued CLNs | Bank issues CLNs directly (no SPV); requires Fed approval for capital recognition | Yes (with approval) | Low (approval-based) | Confirmed |
| Portfolio CDS / guarantees | Unfunded credit protection on retained loan portfolios | If operational criteria met | Very low | Confirmed |
| Private risk-sharing / forward flow | Whole-loan or loss-sharing with private credit funds (e.g. Barclays-Blackstone $1.1bn) | Varies; may not qualify | Very low | Reported |
| Lender risk-sharing (GSE) | Originators share first-loss with GSE on delivered loans | GSE capital framework | Low | Confirmed |
Regulatory Framework
US Capital Rules (Current)
ConfirmedThe current US capital rules (12 CFR §217.41 / §324.41) define synthetic securitisation and allow capital recognition if operational criteria are met, including eligible collateral, guarantee, or credit-derivative protection and restrictions on termination triggers. Confirmed
Recognition is transaction-structure driven rather than a standalone SRT doctrine. For directly issued CLNs, the Fed's 2023 Regulation Q FAQ clarified that SPV-issued CLNs can qualify, while directly issued CLNs may need affirmative approval. Confirmed
OCC Interpretive Letters 1182 (2024) and 988 (2004) show that US supervisors have long addressed synthetic securitisation eligibility through interpretive channels. Confirmed
Basel III Endgame (Status)
ConfirmedThe July 2023 NPR would apply SEC-SA for securitisation exposures and prohibit recognition of synthetic excess spread in synthetic securitisations. Confirmed
In September 2024, Vice Chair Barr said a re-proposal would cover credit, market, and operational risk with reduced scope for banks with $100–250bn in assets. Confirmed
As of March 2026, no newly published joint re-proposal was verified in the Federal Register. The US prudential trajectory remains unsettled. Estimated
Market Size & Activity
GSE CRT — Cumulative Activity (2013–2023)
FHFA| Metric | Cumulative (2013–2023) | 2023 Only | Provenance |
|---|---|---|---|
| Reference pool UPB | $6.664T | $421.8bn | Confirmed |
| Risk in force (RIF) | $210.2bn | $13.0bn | Confirmed |
| RIF from securities (CAS/STACR) | 66% of cumulative | 64% of 2023 | Confirmed |
| RIF from insurance/reinsurance | 29% of cumulative | 36% of 2023 | Confirmed |
| Fannie Mae H1 2025 CRT UPB | — | $139.5bn | Confirmed |
Private bank SRT — What is known
EstimatedThe IMF says that since 2016, more than $1 trillion of assets have been synthetically securitised globally, with recent expansion driven by US banks alongside established European issuers. Confirmed
The Fed's 2024 approvals confirm at least six US banks actively seeking capital recognition for CLN-based synthetic securitisations. However, no comprehensive official US-only issuance series was verified from primary sources. The market appears too private and fragmented for aggregate sizing. Estimated
US vs. Europe Comparison
Regulatory & market comparison
Structured| Dimension | United States | Europe (CRR/CRD) |
|---|---|---|
| Governing framework | Synthetic securitisation definitions + operational criteria (12 CFR §217/§324); directly issued CLNs need Fed approval | CRR Art. 244–245 with dedicated supervisory assessment |
| Supervisor assessment | Institution-specific approval/interpretive letters (Fed, OCC) | ECB case-by-case + fast-track (Dec 2025); PRA SS9/13 |
| "Significance" test | No named equivalent; operational criteria are rule-based | Quantitative + qualitative (EBA GL/2014/05) |
| Market size | GSE CRT: $6.7T UPB / $210.2bn RIF cumulative; private bank SRT: unverified | ~€345bn outstanding (ESRB, Q2 2024); ~€200–500bn (methodology-dependent) |
| Typical structures | GSE notes/insurance; SPV and directly issued CLNs; guarantees; private risk-sharing | Funded CLNs and unfunded guarantees/CDS |
| Protection seller base | Insurers, hedge funds, pensions, asset managers (GSE CRT); broader mix unknown for bank SRT | ~75% credit funds + asset managers (ESRB/ECB survey) |
| Transparency | Strong for GSE CRT; weak for private bank deals; no public tape | Limited but more structured via supervisory reporting |
| Regulatory trajectory | Endgame unsettled (Mar 2026); likely supportive if capital tightens | ECB fast-track live; PRA updated; scrutiny rising |